PRESSEMITTEILUNGEN

Osaka, Japan und Cambridge, Massachusetts (ots/PRNewswire) – Takeda Pharmaceutical Company Limited gab heute gemeinsam mit seiner hundertprozentigen Tochtergesellschaft Millennium: The Takeda Oncology Company bekannt, dass die Europäische Arzneimittel-Agentur (EMA, European Medicines Agency) die Einreichung des Zulassungsantrags (MAA, Marketing Authorization Application) für ADCETRIS(TM) (Brentuximab Vedotin) für die Behandlung des rezidivierten oder refraktären Hodgkin Lymphoms (HL) und [...]

Continue reading

Ash, Authorization Application, Cambridge Massachusetts, Europa, European Medicines, Hematology, Hodgkin Lymphom, Leiden, Marketing, Medical Officer, Medicines Agency, Millennium, Nancy, Oncology, Orphan Medicinal Products, Osaka Japan, Ots, Pharmaceutical Company, Phase Ii, Simonian

Thousand Oaks, California (ots/PRNewswire) – Amgen today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of XGEVA(TM) (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in [...]

Continue reading

Amgen, Bone Metastases, Cause Disability, Clinical Benefit, Denosumab, European Medicines, Healthcare System, Major Surgery, Market Exclusivity, Medical Officer, Medicines Agency, Metastases, Pathological Fracture, Prnewswire, Related Events, Senior Vice President, Spinal Cord Compression, Thousand Oaks California, Today Announced That, Zometa

Washington (ots/PRNewswire) – Novocure gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) das NovoTTF-100A System (NovoTTF) für die Behandlung von erwachsenen Patienten mit Rezidiv-Glioblastoma (Glioblastoma multiforme – GBM)-Hirntumoren nach dem Wiederauftreten eines Tumors, der mit einer Chemotherapie behandelt wurde, zugelassen hat. Das tragbare Gerät bietet eine antimiotische Krebsbekämpfungstherapie, während die Patienten ihren [...]

Continue reading

Chemotherapie, Dr Med, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Gbm, Glioblastoma Multiforme, Medical Officer, Mit, Ots, Photo, Photos, Tumor, Tumors, Vereinigten Staaten

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Research & Development Heidelberg (euro adhoc) – SYGNIS enters final stage with its Phase II efficacy study of AX200 for the treatment of acute stroke – more than 75% of the AXIS 2-patients recruited – Data [...]

Continue reading

Acute Ischemic Stroke, Adhoc, Biotech Company, Clinical Stage, Corporate News, Data Safety Monitoring Board, Dr Frank, Dsmb, Efficacy Study, Independent Data, Ischemic Stroke, Isin, Issues With Regard, Medical Officer, Patient Recruitment, Pharmaceutical Company, Prime Standard, Safety Issues, Safety Monitoring Board, Safety Profile

——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Forschung/Entwicklung Heidelberg (euro adhoc) – Pressemitteilung SYGNIS’ Wirksamkeitsstudie für AX200 zur Behandlung des akuten Schlaganfalls geht in finale Phase * Über 75% der für die AXIS 2-Studie erforderlichen Patienten rekrutiert * Data Safety Monitoring Board bestätigt bisherige Empfehlung zur Fortführung [...]

Continue reading

Adhoc, Axis, Corporate News, Data Safety Monitoring Board, Dr Frank, Dsmb, Euro, Finale, Forschung Entwicklung, Frankfurt, Heidelberg, Isin, Medical Officer, Pharma, Phase Ii, Prime Standard, Safety Monitoring Board, Sehr Gut

San Francisco and Tokyo, November 30 (ots/PRNewswire) – Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with [...]

Continue reading

Androgen Receptor, Astellas Pharma Inc, Comprehensive Development, Double Blind Placebo, Endpoint, Endpoints, Europe Australia, Free Survival, Global Agreement, Investigational Drug, Medical Officer, Medivation Inc, Patient Enrollment, Positive News, Prnewswire, Prostate Cancer, Prostate Cancer Patients, Receptor Antagonist, Seely, Steve Ryder

——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– C.E.O. Interviews 28.10.2010 Ad-hoc Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG Heidelberg, 28 October 2010 – SYGNIS Pharma AG [...]

Continue reading

28 October, Adhoc, Calendar Year, Cdax, Chief Financial Officer, Dr Bach, Dr Frank, Eans, General Counsel, Isin, Lio, Management Contract, Medical Officer, Mutual Consent, Pharma, Prime Standard, Supervisory Board, Vp Operations, Werner Haas, Willinger

Peking, June 24, 2010 (ots/PRNewswire) – Cellonis, ein in Peking und in Hongkong ansässiges Unternehmen, hat mit seinem neuen, personalisierten Konzept für die Behandlung von Diabetes eine bemerkenswerte Verbesserung des Zustands bei behandelten Patienten bewiesen. Die anhaltende klinische Studie belegt, dass im besten Fall die natürliche Insulinproduktion eines Patienten rekonstruiert und sogar spätere Komplikationen wie [...]

Continue reading

Als, Chase, Diabetes, Hongkong, Insulin, June 24, Medical Officer, Ots, Peking, Prnewswire

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Research & Development/Biotechnology Durham, NC (euro adhoc) – Press Release Oxygen Biotherapeutics Inc.: Study Shows Marked Neuroprotective Effects of Oxycyte® Perfluorocarbon Emulsion in a Rat Model of Spinal Cord Injury DURHAM, NC, June 3, 2010 [...]

Continue reading

Adhoc, Emulsion, Functional Recovery, Gerald Klein, Hotel In Las Vegas, Information Research, Medical Officer, Medicine Studies, Miller School, Neurotrauma, Oxycyte, Oxygen Therapy, Paris Hotel In Las Vegas, Poster Sessions, Proof Of Concept, Rat Model, Release Oxygen, Spinal Cord, Spinal Cord Injury, University Of Miami Miller School Of Medicine

——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Unternehmen/Forschung/Entwicklung/Biotechnologie/ Durham, NC (euro adhoc) – Medienmitteilung Oxygen Biotherapeutics Inc.: Neuroprotektive Wirkung von Oxycyte®. Zwei neue Studien belegen die Wirkung von Perfluorcarbon bei Rückenmarksverletzung im Mausmodell Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) gibt heute die Ergebnisse zweier Studien der University of [...]

Continue reading

14 Bis, Adhoc, Biotechnologie, Corporate News, Dr Med, Gerald Klein, Hotel In Las Vegas, Medical Officer, Miller School, Nasdaq, Neurotrauma, Oxycyte, Oxygen Therapy, Paris Hotel In Las Vegas, School Of Medicine, Spinal Cord, Spinal Cord Injury, University Of Miami, University Of Miami Miller School Of Medicine, Vegas Usa

Basel, Switzerland, May 20, 2010 (ots/PRNewswire) – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III PRIMA study. The data showed that continuing MabThera (rituximab) for two years in patients who responded to initial treatment with MabThera plus chemotherapy, doubled the likelihood of them living without their disease worsening, known as [...]

Continue reading

American Society Of Clinical Oncology, Basel Switzerland, Follicular Lymphoma, Free Survival, Hazard Ratio, Incurable Cancer, Initial Treatment, Line Maintenance, Lymphoma, Medical Officer, Meeting Will Take Place, Otcqx, Ots, Phase Iii, Prnewswire, Rhhby, Rituximab, Rog, Safety Profile, Safety Signals

Leiden, Niederlande, und Seattle, March 11, 2010 (ots/PRNewswire) – Das führende Unternehmen ProFibrix B.V., das in der Entwicklung innovativer Produkte zur Blutstillung und für die regenerative Medizin tätig ist, gab heute bekannt, die erste Phase-II-Studie zu seinem einzigartigen neuen Hämostatikum Fibrocaps(TM) abgeschlossen zu haben. Laut vielversprechender vorläufiger Daten, die im Rahmen der europäischen offenen Multicenter-Studie [...]

Continue reading

College Of Pharmacy, Cv Therapeutics, Dr Med, Fibrogen Inc, Genentech, Kanada, Leiden, March 11, Medical Officer, Pharmazie, Phase Ii, Prnewswire, Profibrix, Schloss, School Of Medicine, Seattle, Umfangreiche Erfahrungen, University Of Pennsylvania, University Of Texas

Paris, Frankreich – 16. November 2009 – (ots) – Das RealiseAF-Register wird dazu beitragen, das kardiovaskuläre Risikoprofil von Vorhofflimmerpatienten besser zu definieren und zu verstehen sowie kardiovaskuläre Folgen besser zu charakterisieren Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) gab heute den Start des RealiseAF-Registers bekannt (Real life global Survey Evaluating patients with Atrial Fibrillation), einem internationalen [...]

Continue reading

16 November, Asien, Europa, Fibrillation, Frankreich, Global Survey, Investitionen, Jean Pierre, Lateinamerika, Lehner, Medical Officer, Nyse, Paris, Population, Sanofi Aventis, Sny, Vhf

Paris, November 16 (ots/PRNewswire) – – The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the launch of the RealiseAF registry (Real Life global Survey Evaluating patients with Atrial Fibrillation), an international, cross-sectional, observational [...]

Continue reading

America Asia, Atrial Fibrillation, Broad Spectrum, Cardiovascular Outcomes, Cardiovascular Risk, Global Burden, Global Survey, Health Burden, Hopital Bichat, Lehner, Medical Officer, North Africa, Prnewswire, Risk Profile, Risk Profiles, Sanofi Aventis, Sny, Therapeutic Solutions, Transient Causes, True Impact